MedTrace Logo

Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF

NCT00621179 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-08-10

Study results available
· View outcomes & findings →

Summary

This prospective randomized trial evaluates whether one can predict which infertile women with endometriosis who are candidates for in vitro fertilization will benefit from prolonged therapy with a GnRH agonist by the determination of the absence of endometrial expression of the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for in vitro fertilization and then undergo randomization to a three month course of a depot preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian stimulation or standard therapy. prio

Conditions

Interventions

DRUG

Leuprolide acetate in depot suspension

Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3

OTHER

No intervention

Sponsors & Collaborators

  • Colorado Center for Reproductive Medicine

    lead OTHER

Principal Investigators

  • Eric S Surrey, M.D. · Colorado Center for Reproductive Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2009-08-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621179 on ClinicalTrials.gov